Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer early ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

For women, ovarian cancer is one of the most feared of all diagnoses. Sneaking up silently, often with few symptoms, the ...

The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

After being described in 2018, researchers knew they had something interesting with T3p, a single small RNA found in breast ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions ...

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...